Preliminary evidence indicates that antisense particles against PCSK-9 mRNA or anti-PCSK-9 antibodies, able to reduce circulating PCSK-9 levels, might improve NAFLD independent of LDL cholesterol level reduction [119]. The gene discussed is PCSK9; the disease is metabolic dysfunction-associated steatotic liver disease.